A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania

Psychoneuroendocrinology

Volumn 43, Issue , 2014, Pages 52-61

  Kulkarni, Jayashri ^a   Berk, Michael ^b   Wang, Wei ^a   Mu, Ling ^a   Scarr, Elizabeth ^c   Van Rheenen, Tamsyn E ^a   Worsley, Roisin ^a,d   Gurvich, Caroline ^a   Gavrilidis, Emorfia ^a   De Castella, Anthony ^a   Fitzgerald, Paul ^a   Davis, Susan R ^d  

^a Australia   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d ALFRED HOSPITAL   (Australia)

Author keywords

Bipolar disorder; Mania; Medroxyprogesterone acetate; Schizoaffective disorder; Tamoxifen; Treatment

Indexed keywords

CARBAMAZEPINE; ESTROGEN; LITHIUM SALT; LUTEINIZING HORMONE; MEDROXYPROGESTERONE; MOOD STABILIZER; PLACEBO; PRASTERONE; PROGESTERONE; PROLACTIN; PROTEIN KINASE C; TAMOXIFEN; TESTOSTERONE; VALPROIC ACID; ANTIESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MANIA; PILOT STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BLOOD; MIDDLE AGED; PSYCHOLOGY;

ADULT; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MEDROXYPROGESTERONE; MIDDLE AGED; PROTEIN KINASE C; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84897373939     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.02.004     Document Type: Article

References (40)

1. Altman E.G., Hedeker D.R., Janicak P.G., Peterson J.L., Davis J.M. The Clinician-Administered Rating Scale for Mania (CARS-M): development, reliability, and validity. Biol. Psychiatry 1994, 36:124-134.
2. American Psychiatric Association Diagnostics and Statistical Manual of Mental Disorders, text revised 2000, APA, Washington, DC. 4th ed.
3. Amrollahi Z., Rezaei F., Salehi B., Modabbernia A.-H., Maroufi A., Esfandiari G.-R., Naderi M., Ghebleh F., Ahmadi-Abhari S.-A., Sadeghi M., Tabrizi M., Akhondzadeh S. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J. Affect. Disord. 2011, 129:327-331.
4. Bebchuk J.M., Arfken C.L., Dolan-Manji S., Murphy J., Hasanat K., Manji H.K. A preliminary investigation of a protein kinace C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry 2000, 57:95-97.
5. Berenson A.B., Asem H., Tan A., Wilkinson G.S. Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder. Obstet. Gynecol. 2011, 118:1331-1336.
6. Blaustein J.D., Brown T.J. Progesterone decreases the concentration of hypothalamic and anterior pituitary estrogen receptors in ovariectomized rats. Brain Res. 1984, 304:225-236.
7. Buwalda B., Schagen S.B. Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?. Life Sci. 2013, 93:581-588.
8. Chouinard G., Steinberg S., Steiner W. Estrogen-progesterone combination: another mood stabilizer?. Am. J. Psychiatry 1987, 144:826.
9. Cohen I., Figer A., Tepper R., Shapira J., Altaras M.M., Yigael D., Beyth Y. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol. Oncol. 1999, 72:202-207.
10. Craig M.C. Should psychiatrists be prescribing oestrogen therapy to their female patients?. Br. J. Psychiatry 2013, 202:9-13.
11. Dias R.S., Lafer B., Russo C., Debbio A.D., Nierenberg A.A., Sachs G.S., Joffe H. Longitudinal follow-up of bipolar disorder in women with premenstrual exacerbation: findings from STEP-BD. Am. J. Psychiatry 2011, 168:386-394.
12. DiazGranados N., Zarate C. A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr. Psychiatry Rep. 2008, 10:510-519.
13. Einat H., Peixiong Y., Szabo S.T., Dogra S., Manji H.K. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007, 55:123-131.
14. Freeman M.P., Smith K.W., Freeman S.A., McElroy S.L., Kmetz G.E., Wright R., Keck P.E. The impact of reproductive events on the course of bipolar disorder in women. J. Clin. Psychiatry 2002, 63:284-287.
15. Friedman E., Hoau Yan W., Levinson D., Connell T.A., Singh H. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol. Psychiatry 1993, 33:520-525.
16. Geddes J.R., Miklowitz D.J. Treatment of bipolar disorder. Lancet 2013, 381:1672-1682.
17. Goldstein J.A. Danazol and the rapid-cycling patient. J. Clin. Psychiatry 1986, 47:153-154.
18. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, 534-537. US Department of Health, Education and Welfare, Washington, DC.
19. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W., Sherman S., Sluss P.M., de Villiers T.J. Executive summary of the stages of reproductive aging workshop+10: addressing the unfinished agenda of staging reproductive aging. Fertil. Steril. 2012, 97:843-851.
20. Hox J.J. Multilevel analysis: Techniques and applications 2010, Routledge, New York. 2nd ed.
21. Irwin R.W., Yao J., Ahmed S.S., Hamilton R.T., Cadenas E., Brinton R.D. Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function. Endocrinology 2011, 152:556-567.
22. Kulkarni J., de Castella A., Fitzgerald P.B. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 2008, 65:955-960.
23. Kulkarni J., Garland K.A., Scaffidi A., Headey B., Anderson R., de Castella A., Fitzgerald P., Davis S.R. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006, 31:543-547.
24. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., Burger H. Estrogen - a potential treatment for schizophrenia. Schizophr. Res. 2001, 48:137-144.
25. Lam H.-Y.P. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem. Biophys. Res. Commun. 1984, 118:27-32.
26. Lawrie T.A., Justus Hofmeyr G., De Jager M., Berk M., Paiker J., Viljoen E. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br. J. Obstet. Gynaecol. 1998, 105:1082-1090.
27. Manji H.K., Lenox R.H. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol. Psychiatry 1999, 46:1328-1351.
28. Marsh W.K., Ketter T.A., Crawford S.L., Johnson J.V., Kroll-Desrosiers A.R., Rothschild A.J. Progression of female reproductive stages associated with bipolar illness exacerbation. Bipolar Disord. 2012, 14:515-526.
29. Muthén L.K., Muthén B.O. Mplus user's guide 1998-2013, Muthén & Muthén, Los Angeles, CA, Available as a download at http://www.statmodel.com/ugexcerpts.shtml. sixth ed.
30. Nelson M.V. Interaction of danazol and carbamazepine. Am. J. Psychiatry 1988, 145:768-769.
31. Paganini-Hill A., Clark L.J. Preliminary assessment of cognitive function inbreast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 2000, 64:165-176.
32. Payne J.L., Roy P.S., Murphy-Eberenz K., Weismann M.M., Swartz K.L., McInnis M.G., Nwulia E., Mondimore F.M., MacKinnon D.F., Miller E.B., Nurnberger J.I., Levinson D.F., DePaulo J.R., Potash J.B. Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. J. Affect. Disord. 2007, 99:221-229.
33. Pereira M., Martynhak B.J., Baretta I.P., Correia D., Siba I.P., Andreatini R. Antimanic-like effect of tamoxifen is not reproduced by acute or chronic administration of medroxyprogesterone or clomiphene. Neurosci. Lett. 2011, 500:95-98.
34. Rasgon N., Bauer M., Elman S., Whybrow P.C. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disord. 2003, 5:48-52.
35. Rasgon N.L., Reynolds M.F., Elman S., Saad M., Frye M.A., Bauer M., Altshuler L.L. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J. Affect. Disord. 2005, 89:217-225.
36. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
37. Van Der Leeden R. Multilevel analysis of repeated measures data. Qual. Quant. 1998, 32:15-29.
38. Yildiz A., Guleryuz S., Ankerst D., Öngür D., Renshaw P.F. Protein kinase c inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch. Gen. Psychiatry 2008, 65:255-263.
39. Yildiz A., Vieta E., Leucht S., Baldessarini R.J. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Am. Coll. Neuropsychopharmacol. 2011, 36:375-389.
40. Zarate C.A., Singh J.B., Carlson P.J., Quiroz J., Jolkovsky L., Luckenbaugh D.A., Manji H.K. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007, 9:561-570.